|
CRYBG3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64280034020692E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.61869994974984E-10 |
| Normal-vs-Stage2 |
3.38629999596662E-08 |
| Normal-vs-Stage3 |
9.76489999970909E-11 |
| Normal-vs-Stage4 |
2.2252200082562E-12 |
| Stage1-vs-Stage2 |
5.906000E-01 |
| Stage1-vs-Stage3 |
2.844600E-01 |
| Stage1-vs-Stage4 |
2.755000E-04 |
| Stage2-vs-Stage3 |
1.918230E-01 |
| Stage2-vs-Stage4 |
4.343300E-03 |
| Stage3-vs-Stage4 |
2.747600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.8650003763554E-10 |
| Normal-vs-AfricanAmerican |
1.64529999624463E-08 |
| Normal-vs-Asian |
3.21399573621761E-11 |
| Caucasian-vs-AfricanAmerican |
9.329000E-01 |
| Caucasian-vs-Asian |
1.710210E-01 |
| AfricanAmerican-vs-Asian |
4.335200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.85750345397196E-11 |
| Normal-vs-Female |
2.87539991816743E-10 |
| Male-vs-Female |
2.781400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.36419997520676E-09 |
| Normal-vs-Age(41-60Yrs) |
1.90919946518875E-10 |
| Normal-vs-Age(61-80Yrs) |
1.8279044944336E-11 |
| Normal-vs-Age(81-100Yrs) |
2.784000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.352000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.531800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.663400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.314800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.439400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.186000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.976200E-01 |
| Classical-VS-Follicular |
1.896640E-01 |
| Classical-VS-Other |
3.787400E-01 |
| Classical-VS-Normal |
3.23580051642125E-10 |
| Tall-VS-Follicular |
9.257600E-02 |
| Tall-VS-Other |
4.741600E-01 |
| Tall-VS-Normal |
2.0330004346647E-10 |
| Follicular-VS-Other |
2.853400E-01 |
| Follicular-VS-Normal |
4.54649999870327E-08 |
| Other-VS-Normal |
3.83139999999837E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.38990049972188E-10 |
| Normal-vs-N1 |
4.58160176464162E-11 |
| N0-vs-N1 |
2.496200E-01 |
|
|
